



Endari in Egypt

The EDA named-patient coordination pathway — indicative 2026

HEMATOLOGY · SICKLE CELL DISEASE (AGE 5+)

The clinical situation

Endari (L-glutamine oral powder) is FDA-approved to reduce acute complications of sickle cell disease (SCD) in adults and paediatric patients aged 5 years and older. Manufactured by Emmaus Medical, it is an oral amino-acid formulation that replenishes NAD⁺ precursor capacity in sickle red blood cells, reducing oxidative stress and vaso-occlusive crises in pivotal-trial data. Hydroxyurea remains the backbone of SCD disease modification; Endari is typically added when crisis frequency remains high. Weight-based dosing (5/10/15 g twice daily), mixed with 8 oz of beverage or 4–6 oz of soft food. Well-tolerated profile; Oxbryta and Adakveo have had revised global status — Endari remains commercially available with a distinct safety profile.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your haematologist confirms SCD diagnosis (haemoglobin electrophoresis), documents crisis history, current hydroxyurea regimen, and the rationale for Endari as add-on.
- 2 EDA named-patient application.** Physician files dossier: clinical letter, patient reference (paediatric if applicable), product details, weight-based dosing plan.
- 3 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed specialty wholesale partner.
- 4 Shipment.** Controlled-room-temperature shipment with importer-of-record handling.
- 5 Arrival & dosing start.** Treating haematologist initiates weight-based oral powder dosing twice daily.

Indicative economics

Reference US cash-pay range: USD 30,000–50,000 annualised at US list for adult dosing (weight-based; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

14–21 days from a complete EDA application to first dispensed supply, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your haematologist and EDA review, keyed to the SCD therapy rationale. **Logistics.** Controlled-room-temperature shipment with importer-of-record handling. **Concierge case lead.** Named point of contact for family and care team. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating haematologist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Endari × Egypt first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/endari-egypt.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team